JOHNSON & JOHNSON (JNJ)

Expected Trial Completion: CFAE/spatiotemporal Dispersion Guided Ablation vs PVI Guided Ablation in Persistent AF

The clinical trial "Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide" (Clinical Trial ID: NCT05256940) is designed to compare a revised version of Motivational Interviewing (MI-SI-R) combined with enhanced usual care (EUC) against EUC alone in a population of 470 high-risk veterans with recent suicidal crises. The trial aims to address the ambivalence towards living in this demographic and reduce suicide attempts, building upon preliminary results showing significant reductions in both suicide attempts and suicidal ideation. The expected trial completion date is June 29, 2027, with the study currently in the recruiting phase.

Expected completion of clinical trial for contact lenses

The clinical trial titled "Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide" is expected to complete on June 29, 2027. Sponsored by the VA Office of Research and Development, this trial investigates a modified approach to motivational interviewing aimed at reducing suicidal ideation and attempts among high-risk veterans. The study involves 470 participants, comparing a revised motivational interviewing method alongside enhanced usual care against usual care alone. Preliminary results indicated that the new approach significantly decreased suicide attempts and suicidal thoughts when integrated with standard care.

Start Date of INTeGRATE Clinical Trial

Abiomed Inc. has announced the start of the INTeGRATE clinical trial on December 1, 2025, which will evaluate the efficacy of the Impella 5.5 device in improving guideline-directed medical therapy (GDMT) in heart failure patients experiencing cardiogenic shock. This multi-center, post-market study aims to assess the impact of Impella 5.5 on up-titration of GDMT during the device's support and the subsequent recovery of heart function at 90 days post-discharge, with a total enrollment of 60 patients. The trial's outcomes will be monitored for one year following hospital discharge. JNJ is the related company involved.

• www.clinicaltrials.gov/study/NCT06965504

Expected Completion of Clinical Trial on Vitamin D in Preterm Infants

A clinical trial studying the effect of supplemental vitamin D in the diets of preterm infants is expected to complete in December 2025. Sponsored by Baylor College of Medicine, the trial assesses if added vitamin D in transitional formulas can improve serum vitamin D levels in infants born at less than 35 weeks of gestation. Currently, 39 participants have enrolled, and the status remains active but not recruiting. The research aims to determine the efficacy of vitamin D in preventing low serum levels among vulnerable infants. This study could have implications for infant nutrition guidelines, impacting healthcare providers.

• www.clinicaltrials.gov/study/NCT01698840

Expected Completion of C-Section Wound Closure Clinical Trial

Johnson & Johnson's clinical trial examining the efficacy of standard C-section wound closure compared to a combination of STRATAFIX sutures and DERMABOND PRINEO is expected to complete on December 1, 2025. This trial, conducted by North York General Hospital, aims to assess patient-reported experiences and outcomes following cesarean delivery. The study is currently in the recruiting phase with 68 participants enrolled and is anticipated to provide insights that could affect clinical practices regarding wound closure methods in cesarean deliveries.

• www.clinicaltrials.gov/study/NCT06614829

Expected Completion of Clinical Trial NCT06887920

The clinical trial NCT06887920, sponsored by Pauline Kang at The University of New South Wales, is expected to complete on December 1, 2025. The study compares the effects of MiSight 1-Day contact lenses and Acuvue Oasys for presbyopia on myopic children, specifically assessing myopia progression over a year with an enrollment of 72 participants. As JNJ is the related company, the results may influence their product positioning in the pediatric contact lens market.

• www.clinicaltrials.gov/study/NCT06887920

Completion of Nordic-Baltic Bifurcation Study IV Clinical Trial

The Nordic-Baltic Bifurcation Study IV Clinical Trial, sponsored by Niels Ramsing Holm at Aarhus University Hospital Skejby, is expected to complete on December 1, 2025. The trial involves 450 patients and evaluates two stenting strategies for bifurcation lesions. The primary endpoint focuses on cardiac death and myocardial infarction rates, projected at 10% for one stent strategy and 3% for two stents after six months. Results will help inform future cardiac procedures and publications in international cardiovascular journals are expected post-trial.

• www.clinicaltrials.gov/study/NCT01496638

Expected Completion of Nordic-Baltic Bifurcation Study IV

The Nordic-Baltic Bifurcation Study IV is a clinical trial examining treatment strategies for patients undergoing coronary bifurcation interventions. The trial, which is currently active but not recruiting, aims to enroll 450 patients and will assess the effectiveness of a single-stent versus dual-stent approach in reducing major adverse cardiac events (MACE). The primary endpoint, expected to be reported after 6 months, includes cardiac death and non-procedure related myocardial infarction. The study is set to be completed by December 1, 2025, and results will be published in an international cardiovascular journal, contributing valuable data to the field of interventional cardiology.

Oral Acetaminophen Clinical Trial Expected Completion Date

Johnson & Johnson (JNJ) is sponsoring a clinical trial at Rutgers University to assess the effectiveness of oral acetaminophen formulations for managing postoperative pain in bariatric surgery patients. Scheduled for completion by May 1, 2026, the trial aims to compare the therapeutic effects of liquid versus pill forms of acetaminophen. As these patients exhibit altered metabolism due to physiological changes from obesity and surgery, the study will involve 150 participants over approximately two years, utilizing a randomized control design. The trial seeks to improve patient outcomes and experiences while addressing opioid alternatives in pain management.

• www.clinicaltrials.gov/study/NCT06658574

Expected Completion of ENTERPRISE 2 Clinical Trial

The expected completion of the ENTERPRISE 2 clinical trial, which focuses on evaluating the safety and effectiveness of the ENTERPRISE 2 device for treating intracranial aneurysms, is slated for September 10, 2026. This multicenter, observational study involves 164 patients with either ruptured or unruptured intracranial aneurysms. The primary endpoint assesses the incidence of aneurysm recanalization after 180 days, while secondary endpoints include various measures of device performance and safety assessments over several years. The trial, sponsored by Medos International SARL, is currently active but not recruiting patients.

• www.clinicaltrials.gov/study/NCT04289480